quantisnow
FeedTopReportsPricing
⌘K
Live feed
11:17:00·65d
PRRelease
Perspective Therapeutics Inc. logo
ImmunityBio Inc. logo
Nuvation Bio Inc. logo
+2

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

CATX· Perspective Therapeutics Inc.IBRX· ImmunityBio Inc.NUVB· Nuvation Bio Inc.NVCR· NovoCure LimitedONCY· Oncolytics Biotech Inc.
Health Care
Original source

Companies

  • CATX
    Perspective Therapeutics Inc.
    Health Care
  • IBRX
    ImmunityBio Inc.
    Health Care
  • NUVB
    Nuvation Bio Inc.
    Health Care
  • NVCR
    NovoCure Limited
    Health Care
  • ONCY
    Oncolytics Biotech Inc.
    Health Care

Recent analyst ratings

  • Mar 12IBRXUpdateBTIG Research$13.00
  • Feb 19CATXUpdatePiper Sandler$16.00
  • Nov 24CATXUpdateTruist$12.00
  • Nov 24NUVBUpdateTruist-
  • Nov 19NUVBUpdateB. Riley Securities$12.00
  • Oct 10CATXUpdateBTIG Research$14.00

Related

  • PR2d
    /U P D A T E -- Nuvation Bio Inc./
  • PR2d
    Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
  • INSIDER2d
    SEC Form 4 filed by Wentworth Kerry
  • INSIDER2d
    SEC Form 4 filed by Liu Dongfang
  • SEC2d
    SEC Form DEFA14A filed by Nuvation Bio Inc.
  • PR2d
    ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
  • SEC3d
    SEC Form DEFA14A filed by NovoCure Limited
  • SEC3d
    SEC Form DEF 14A filed by NovoCure Limited
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022